Pierre Lemieux - 22 Jun 2022 Form 4 Insider Report for Acasti Pharma Inc. (GRCE)

Reporting relationship: COO, Canada & CSO
Issuer ticker: GRCE
Reported as of: 22 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2022, 16:34:40 UTC
Prior SEC filing: 16 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Jason Comerford, attorney-in fact for Mr. Lemieux

Key filing fact

Pierre Lemieux filed Form 4 for Acasti Pharma Inc. (GRCE) on 23 Jun 2022.

Key facts

This page summarizes Pierre Lemieux's Form 4 filing for Acasti Pharma Inc. (GRCE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2022, 16:34.

Change

Previous filing in this sequence was filed on 16 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACST transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +165,000
Change %
Price: $0.000000
Shares after: 165,000
Date: 22 Jun 2022
Ownership: Direct
Underlying class: Class A Common Shares
Underlying amount: 165,000
Exercise price: $0.8900
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant.

Footnote F2

Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months.